OS Therapies raises $7.2M via warrant deal to fund cancer drug filings
What's the deal? OS TherapiesDealroom has a profile for this one. Try Dealroom → has raised approximately $7.2 million in the initial closing of a warrant exercise inducement and exchange offer. Seven accredited holders exercised, or pre-funded the exercise of, warrants to buy 5,517,253 shares at a reduced price of $1.30 each. In return, the NYSE American-listed company (ticker: OSTX) issued new warrants to purchase the same number of shares at $1.40.
What's the endgame? OS Therapies plans to use the net proceeds to support regulatory filings and commercial preparation for Herlystic, its immunotherapy for pulmonary metastatic osteosarcoma. The company intends to submit applications to US, UK, European, and Australian regulators in the fourth quarter of 2026.
Why now? The capital, combined with $7 million in accrued refundable UK research and development tax credits, is expected to carry the company through those upcoming milestones. "We expect the proceeds from this warrant inducement transaction to provide the Company with the capital needed to advance our pending Herlystic early market access submissions," said chair and chief executive officer Paul Romness.
What could go wrong? This is recurring insider financing, not a new institutional round. OS Therapies has leaned on similar warrant deals repeatedly — raising $4.2 million in July 2025, $3.7 million in September 2025, and $7.53 million in January 2026 — underscoring its ongoing need to fund development and regulatory work. The company still faces execution and funding risks before any approval.
The signal: The proceeds are meaningful, but the structure and repeated raises make this a runway extension rather than evidence of a broad new investor commitment. For a small-cap biotech pushing toward multiple regulatory filings, tapping existing holders is becoming the default way to keep the lights on.
Read more: marketscreener.com
Image credit: Generated with Gemini
